Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ziftomenib + venetoclax
- Development stage
- Phase 1
- Lead developer
- Kura Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ziftomenib + venetoclax is an investigational combination therapy for acute myeloid leukemia (AML), particularly for patients with nucleophosmin 1 (NPM1)-mutated or lysine methyltransferase 2A (KMT2A)-rearranged AML. Ziftomenib is a potent, selective small molecule inhibitor of the menin-KMT2A (MLL, KMT2A) protein-protein interaction, a key driver in these AML subtypes, while venetoclax is a BCL-2 inhibitor that induces apoptosis in hematologic malignancies. In preclinical models, combining ziftomenib with venetoclax demonstrates synergistic lethality and improved response in AML. Clinical trials are ongoing to assess the safety, tolerability, and efficacy of this combination in both relapsed/refractory (R/R) and newly diagnosed AML patients[1][2][3][4].
- Other names
- ziftomenibKO-539KO539KO 539Venclexta
02
Targets
BCL-2 (BCL-2 family)KMT2AMEN1 (Menin)
Beyond the preview
Go deeper on ziftomenib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ziftomenib + venetoclax.